The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Retatrutide

C
Animal replicated
Off-labelGLP-1/GIP/Glucagon Triple AgonistPeptideAnti-Obesity Drug
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
LY3437943 — GLP-1/GIP/Glucagon Triple Receptor Agonist — GLP-1/GIP/Glucagon Triple Agonist, Peptide, Anti-Obesity Drug.
Why people use it
Weight Loss · Type 2 Diabetes and Glycemic Control · Cardiovascular Markers · Knee Osteoarthritis · Prediabetes Reversal · Sleep Apnea
What the evidence supports
Retatrutide is the compound that, when approved, will be looked back on as the moment obesity medicine became something fundamentally different from what it was before.
Key risks
Key risks: Pancreatitis history, Severe renal impairment, Pregnancy, Insulin or sulfonylurea users.
If you only read one thing

Reality 1: Retatrutide has produced the highest weight loss ever documented in a Phase 3 human trial — 28.7% at 68 weeks. The data is from randomized, double-blind, placebo-controlled Phase 3 trials conducted by one of the world's most rigorous clinical drug development organizations. The numbers are real. Reality 2: Retatrutide is not FDA-approved, not MHRA-approved, and not approved by any regulatory agency as of May 2026. There is no legal prescription pathway. Approval is expected late 2027 to early 2028 at the earliest. Reality 3: The community is already using research-grade retatrutide obtained from peptide vendors, treating it as 'a stronger version of Mounjaro,' without fully accounting for the pharmacological differences that glucagon receptor agonism introduces — including a sustained heart rate increase and a 20.9% incidence of dysesthesia in Phase 3 that does not occur with semaglutide or tirzepatide. All three realities must be held simultaneously for an honest account of this compound.

Check interactions →
Published literature
5human RCTs0human studies0animal0in vitro
Evidence reality check
Human evidence
5 human studies
5 randomized; 0 observational.
Preclinical base
0 lab signals
0 animal; 0 in-vitro/mechanistic.
Evidence snapshot
Retatrutide is the compound that, when approved, will be looked back on as the moment obesity medicine became something fundamentally different from what it was before.
From the chapter quick-reference block.
Indication map
Supported / plausible / speculative / avoid
Plausible
Weight Loss · Type 2 Diabetes and Glycemic Control · Cardiovascular Markers · Knee Osteoarthritis · Prediabetes Reversal · Sleep Apnea
Retatrutide is the compound that, when approved, will be looked back on as the moment obesity medicine became something fundamentally different from what it was before.
Avoid
Pancreatitis history
GLP-1 class is associated with increased pancreatitis risk. History of pancreatitis warrants avoidance. Monitor lipase and amylase if any abdominal pain develops during treatment.

Retatrutide is the compound that, when approved, will be looked back on as the moment obesity medicine became something fundamentally different from what it was before. The numbers are real. The drug is not yet available. And the community isn't waiting.

The central tension resolved: Three simultaneous realities define this chapter. First: 28.7% mean weight loss at 68 weeks in a Phase 3 trial — the highest weight loss figure ever documented in obesity pharmacology. At the 12 mg dose in TRIUMPH-4, nearly 95% of participants achieved clinically meaningful weight loss, 72% reversed prediabetes, and 75.8% reduction in knee OA pain was achieved as a co-primary endpoint. These are not marginal improvements. They are approaching what bariatric surgery produces, without surgery. Second: Not FDA-approved. Not MHRA-approved. Not available by prescription anywhere in the world as of May 2026. The only legal pathway is clinical trial enrollment. NDA submission is expected Q4 2026. Approval is projected late 2027 to early 2028. Third: The community is using it. Research-grade retatrutide is accessible from peptide vendors. Users who have already been through the semaglutide-to-tirzepatide progression are moving to retatrutide without medical oversight, without the dose escalation monitoring infrastructure that clinical trials provided, and without the full safety picture that the remaining TRIUMPH trials will produce.

The pharmacological distinction from tirzepatide matters more than the community currently appreciates. Retatrutide is not 'Mounjaro Plus.' The glucagon receptor component adds thermogenesis, hepatic fat clearance, a 5-10 bpm sustained heart rate increase, PCSK9-mediated LDL reduction, and — as TRIUMPH-4 demonstrated — dysesthesia in 20.9% of participants at the maximum dose. These are real pharmacological effects from a receptor system that is genuinely different from the GLP-1/GIP dual agonism that tirzepatide uses. The community's assumption that prior GLP-1 experience fully prepares a user for retatrutide's effects is pharmacologically imprecise.

The liver data deserves separate emphasis. The Nature Medicine 2024 substudy produced a 82.4% liver fat reduction at 24 weeks — the most dramatic pharmaceutical liver fat reduction ever documented in a controlled trial. MASLD/NAFLD affects over 100 million Americans, has no approved pharmaceutical treatment, and is a leading cause of liver transplantation and liver-related mortality. If retatrutide's MASLD Phase 3 trial confirms these findings, the drug's clinical importance extends dramatically beyond obesity into the largest unmet need in hepatology.

Categories
Weight Loss & MetabolicGut & DigestiveMitochondrial & Energy
Properties
WADA S0✓ Human RCT
  • ⛔ Pancreatitis history — GLP-1 class is associated with increased pancreatitis risk. History of pancreatitis warrants avoidance. Monitor lipase and amylase if any abdominal pain develops during treatment.
  • ⛔ Severe renal impairment — limited safety data; caution warranted.
  • ⛔ Pregnancy — absolute contraindication. Stop retatrutide (or any GLP-1 agonist) at least 2 months before attempting conception. The drugs are not cleared instantaneously — the long half-life requires this lead time.
  • ⛔ Insulin or sulfonylurea users — retatrutide's glucose-lowering effects can cause hypoglycemia when combined with insulin or sulfonylureas. Physician oversight and dose reduction of the other agents is required.
Half-life
The peptide is modified with a C18 fatty acid chain via a linker to albumin binding, extending its plasma half-life to approximately 6-7 days — enabling the once-weekly subcutan…
Evidence
CAnimal replicated
The Numbers
Phase 2 (NEJM, 2023): 24.2% mean weight loss at 48 weeks on 12 mg. Phase 3 TRIUMPH-4 (December 2025): 28.7% mean weight loss at 68 weeks on 12 mg. For context: semaglutide ~15%, tirzepatide ~22%. Retatrutide is the most effective weight loss compound ever tested in a Phase 3 human trial.
What Makes It Different From Tirzepatide
Tirzepatide = GLP-1 + GIP dual agonist. Retatrutide = GLP-1 + GIP + Glucagon triple agonist. The glucagon receptor component drives additional thermogenesis, hepatic fat clearance, and PCSK9-mediated LDL reduction. This is not just more potent GLP-1/GIP — it is a different pharmacological entity with distinct effects on energy expenditure and lipid metabolism.
Regulatory Status
NOT FDA approved. NOT approved by any regulatory agency as of May 2026. Phase 3 TRIUMPH program underway with 7 additional trials expected to read out in 2026. NDA submission anticipated Q4 2026. FDA approval estimated late 2027 to early 2028. Clinical trial enrollment is the only legal pathway to access in the US.
Community Use Status
Research-grade retatrutide is available from peptide research vendors as lyophilized powder. Community use exists at the time of writing (May 2026). This is off-label, unapproved use of an investigational drug. The chapter covers what the Phase 3 data shows — not community protocols specifically, as there is no validated human dose for community anti-obesity use outside of clinical trials.
The Glucagon Dimension — Key Safety Signal
Retatrutide's glucagon receptor agonism drives a sustained heart rate increase of approximately 5-10 bpm, peaking at week 24. This is distinct from the GLP-1 class effect. It is generally clinically manageable but requires monitoring, particularly in individuals with cardiovascular disease or arrhythmia history. This effect is not seen with semaglutide or tirzepatide at comparable doses.
Dysesthesia — New Phase 3 Finding
TRIUMPH-4 identified dysesthesia (abnormal sensory sensations — tingling, burning, heightened skin sensitivity) in 20.9% of participants at 12 mg and 17.5% at 9 mg. This adverse effect is unique to retatrutide among the GLP-1 class and is likely related to the glucagon receptor component. It is generally mild and manageable but should be understood before initiating any protocol.
Liver Fat — The Most Dramatic Finding
Phase 2a liver substudy (Harrison et al., Nature Medicine 2024): 12 mg retatrutide reduced liver fat by 82.4% at 24 weeks; 86% of participants achieved normal liver fat (<5%). This is the most dramatic pharmaceutical liver fat reduction ever documented in a controlled trial. Glucagon receptor agonism is believed to be the key driver.
Standard Clinical Trial Dosing
Phase 2 and 3 dosing: 1 mg → 4 mg → 8 mg → 12 mg once weekly SubQ, dose escalated over 4-8 weeks to improve GI tolerability. The 12 mg maintenance dose produced the headline weight loss results. 9 mg also showed 26.4% weight loss in Phase 3.
Thyroid / MTC Warning
Class warning applies: GLP-1 agonists carry a precautionary warning for medullary thyroid carcinoma based on rodent data. Not confirmed in humans. Absolute contraindication for personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
WADA Status
Not currently listed on the 2026 WADA Prohibited List. GLP-1 class compounds are not banned for athletes. However, retatrutide's metabolic-enhancing effects (thermogenesis, fat oxidation via glucagon) may attract regulatory scrutiny as the drug class evolves. Current status: athletes can use without known WADA violation.
Muscle Loss Concern
Rapid weight loss with GLP-1/GIP/glucagon agonists includes muscle loss alongside fat loss. The community's most important countermeasure: high protein intake (1.6-2g/kg body weight) and resistance training. Retatrutide-specific muscle preservation data is limited; the class concern applies.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Mazdutide
C
Same class · Peptide

The World's First Approved Dual GCG/GLP-1 Receptor Agonist. NMPA-Approved in China June 2025 for Obesity. Second NMPA Approval September 2025 for T2D. Phase 3 T2D Data Published Back-to-Back in Nature December 2025. Originally Eli Lilly's LY3305677 — Licensed to Innovent Biologics for China Development. No FDA Submission as of Mid-2026. The Drug That Is Simultaneously Approved, Unavailable, and a Research Chemical Depending on Where You Are.

Survodutide
C
Same class · Peptide

The Glucagon Rehabilitation Story. Phase 2 MASH (NEJM July 2024): 62% MASH Resolution vs 14% Placebo. Phase 3 SYNCHRONIZE-1 (April 2026): -16.6% Weight Loss at 76 Weeks. FDA Breakthrough Therapy for MASH September 2024. LIVERAGE Phase 3 MASH Ongoing. Why Glucagon in Metabolic Disease? The GLP-1 + GCGR Advantage Over GLP-1 + GIPR for Liver Disease. The Most Important Obesity Drug for MASH Patients That Nobody in the Community Has Heard Of.

Cagrilintide
C
Same class · Peptide

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

Check interactions